Potential drug development and therapeutic approaches for clinical intervention in COVID-19

Bioorg Chem. 2021 Sep:114:105016. doi: 10.1016/j.bioorg.2021.105016. Epub 2021 May 25.

Abstract

While the vaccination is now available to many countries and will slowly dissipate to others, effective therapeutics for COVID-19 is still illusive. The SARS-CoV-2 pandemic has posed an unprecedented challenge to researchers, scientists, and clinicians and affected the wellbeing of millions of people worldwide. Since the beginning of the pandemic, a multitude of existing anti-viral, antibiotic, antimalarial, and anticancer drugs have been tested, and some have shown potency in the treatment and management of COVID-19, albeit others failed to leave any positive impact and a few also became controversial as they showed mixed clinical outcomes. In the present article, we have brought together some of the candidate therapeutic drugs being repurposed or used in the clinical trials and discussed their clinical efficacy and safety for COVID-19.

Keywords: COVID-19; Clinical Trials; Coronavirus; Drug development; SARS-CoV-2; Therapeutics.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / chemistry
  • Antiviral Agents / therapeutic use*
  • COVID-19 / epidemiology
  • COVID-19 / virology
  • COVID-19 Drug Treatment*
  • Clinical Trials as Topic
  • Drug Development*
  • Drug Repositioning
  • Humans
  • Pandemics
  • SARS-CoV-2 / classification
  • SARS-CoV-2 / physiology*

Substances

  • Antiviral Agents